Understanding the evolution of drug resistance points to novel strategy for developing better antimicrobials
October 29, 2013
The most common fungal pathogen in humans, Candida albicans, rarely develops resistance to the antifungal drug amphotericin B (AmB). This has been puzzling as the drug has been in clinical use for over 50 years. Whitehead Institute scientists have now discovered why. The genetic mutations that enable certain strains of C. albicans to resist AmB simultaneously render it highly susceptible to environmental stressors and disarm its virulence factors.